Sihuan Bio: Plans to acquire 80% of Changyuan Pharmaceutical's equity for 160 million yuan in cash.

Sihuan Biotech announced that the company plans to acquire 80% equity of Jilin Changyuan Pharmaceutical Co., Ltd. held by Jiangxi Jixin Biotechnology Co., Ltd. for cash, with a tentative transfer price of 160 million RMB. The company convened a board meeting on August 17, 2026, to review and approve the relevant proposals and signed a letter of intent for the equity transfer. This transaction is still in the planning stage and further negotiation on whether to sign a formal acquisition agreement will depend on the results of due diligence, auditing, and assessment. There remains uncertainty about whether the final transaction can be completed.